A Phase 3 interventional study of rituximab [MabThera/Rituxan] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Serbia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-21.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 57th largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 44th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 129th largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 181st registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment. All patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and methotrexate (10-25mg po) weekly. The anticipated time on study treatment is 3-12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate · Drug: methylprednisolone
Drug page: Rituximab
1000 mg iv Days 1 and 15
10 - 25 mg/week
iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24
DAS28 was calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and patient's global assessment (PGA) of disease activity (participant-rated arthritis activity assessment using visual analog scale \[VAS\]) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
Time frame: Baseline, Week 24
Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 24
| Milestone | Rituximab/Methylprednisolone/Methotrexate (MTX) |
|---|---|
| Started | 15 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
DAS28 was calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hour\]) and patient's global assessment (PGA) of disease activity (participant-rated arthritis activity assessment using visual analog scale \[VAS\]) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
| score on a scale | Rituximab/Methylprednisolone/MTX |
|---|---|
| Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24 | 2.98 ± 1.80 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| score on a scale | Rituximab/Methylprednisolone/MTX |
|---|---|
| Baseline | 1.91 ± 0.687 |
| Week 24 | 1.05 ± 0.960 |
Collected over Adverse events (AEs) were reported starting with the first dose of study drug through the end of the study (24 weeks total).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab/Methylprednisolone/MTX | — | 2/14 (14.3%) | 0/14 (0%) |
| Event | Rituximab/Methylprednisolone/MTX |
|---|---|
| Infarctus myocardiiCardiac disorders | 1/14 |
| Enterocolitis acutaGastrointestinal disorders | 1/14 |
Per-protocol (PP) population: The 14 enrolled participants who were compliant with the protocol and not lost to follow-up.
| Age, Continuous(years) | Rituximab/Methylprednisolone/MTX |
|---|---|
| Mean | 52.29 ± 11.89 |
| Age, Categorical(Participants) | Rituximab/Methylprednisolone/MTX |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 13 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Rituximab/Methylprednisolone/MTX |
|---|---|
| Female | 9 |
| Male | 5 |
| Race (NIH/OMB)(Participants) | Rituximab/Methylprednisolone/MTX |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Rituximab/Methylprednisolone/MTX |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Rituximab/Methylprednisolone/MTX |
|---|---|
| Serbia | 14 |
Ran from Aug 2006 to primary completion in Nov 2007, 15 months.
Results were first posted in Nov 2014, 6 years 11 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 15 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Methotrexate